Rarity Bioscience

Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University

Mutation detection,mrd,liquid biopsy, in vitro diagnostics,oncology,cancer research,relapse monitoring,cancer diagnostics,flowcytometry,pcr,superrca,mutation testing in blood and bone marrow,leukemia,molecular mrd,clinical flow cytometry,molecular diagnostics,laboratory services,flow cytometry,sample mutation analysis,cfdna,and ctdna

Rarity bioscience operates in the Biotechnology industry.

Rarity bioscience's revenue is 11m - 100m

Rarity bioscience has 11 - 50 employees.